one
hallmark
class
viral
fusion
protein
peripheri
envelop
virus
human
immunodefici
viru
type
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
trigger
format
trimerofhairpin
motif
critic
prelud
fusion
viru
target
cell
trimerofhairpin
arguabl
typic
exampl
coiledcoil
sixhel
bundl
ntermin
heptad
repeat
nhr
viral
envelop
glycoprotein
env
subunit
form
central
trimer
coiledcoil
inner
core
three
ctermin
heptad
repeat
chr
pack
obliqu
antiparallel
manner
fig
previou
studi
indic
extend
prehairpin
intermedi
exist
trimer
nhr
coiledcoil
chr
motif
inhibit
transit
fold
prehairpin
intermedi
fusogen
signific
biomed
potenti
interrupt
process
membran
fusion
stop
viral
first
proof
concept
came
studi
peptid
correspond
chr
region
ie
enfuvirtid
fuzeon
approv
us
fda
first
fusion
paradigm
establish
launch
identif
new
line
analog
chr
peptidebas
fusion
inhibitor
class
viral
fusion
protein
promis
antivir
sharp
contrast
peptid
deriv
nhr
region
fusion
protein
gener
much
less
potent
inhibitor
chr
peptid
develop
antivir
agent
hamper
linear
nhr
peptid
aggreg
physiolog
condit
automat
form
natur
occur
trimer
coiledcoil
structur
prerequisit
interact
complementari
chr
therefor
effort
direct
toward
prepar
stabl
solubl
ntrimer
mimet
includ
construct
sever
chimer
molecul
introduc
exogen
trimer
motif
portion
nhelix
stabil
trimer
oligom
disulfid
howev
modif
suffer
extralarg
auxiliari
protein
domain
may
attenu
antivir
activ
nhrtrimer
use
antigen
nonrelev
portion
peptid
chimera
might
induc
undesir
immun
moreov
exogen
motif
might
divert
real
conform
nhr
trimer
prefusogen
state
thu
thwart
applic
drug
target
screen
small
identifi
therapeut
via
mirror
imag
phage
isopeptid
bond
present
rang
bacteri
pilu
structur
give
extraordinari
stabil
capsid
face
sever
mechan
chemic
proteolyt
semin
work
investig
stabil
de
novo
design
coiledcoil
interact
suggest
isopeptid
bond
de
novo
coiledcoil
assembl
add
except
resist
herein
report
synthet
approach
construct
nhr
trimer
coil
coil
homolog
natur
occur
protein
sequenc
antivir
therapeut
approach
take
advantag
sever
rulesofthumb
coiledcoil
trimer
translat
isopeptid
bridgeteth
structur
design
simpl
sequenc
challeng
nativ
protein
coil
coil
chose
nhr
peptidebas
fusion
inhibitor
templat
studi
base
low
capac
sequest
nonaggreg
helic
trimer
conform
true
reflect
practic
challeng
broader
recapitul
nhr
trimer
class
fusion
protein
three
peptid
form
central
coiledcoil
core
use
hydrophob
residu
posit
helic
selfassoci
hydrophob
residu
facilit
bind
residu
target
peptid
fig
accumul
evid
shown
pack
interact
ile
residu
hydrophob
core
favor
trimer
coiledcoil
assembl
interhel
intrahel
ionic
interact
crucial
control
protein
fold
accord
comput
model
design
principl
three
deriv
ie
design
facilit
npeptid
trimer
fig
design
residu
gln
residu
leu
locat
posit
respect
replac
ile
residu
residu
gln
g
posit
residu
leu
e
posit
substitut
posit
neg
charg
residu
respect
form
favor
interhel
electrostat
interact
base
structur
design
intrastrand
salt
bridg
introduc
posit
helic
conform
respect
enhanc
stabil
coiledcoil
assembl
furthermor
envis
replac
weak
interhel
ionic
bond
posit
isopeptid
bridg
would
offer
attract
option
stabil
trimer
coiledcoil
conform
engin
deriv
consequ
side
chain
residu
glu
mutant
describ
modifi
benzyl
thioester
fig
result
peptid
sbn
sbn
sbn
use
acyl
transfer
intermedi
gener
coval
stabil
trimer
nhr
oligom
ie
via
acyl
transfer
reaction
fig
mutant
first
analyz
use
sediment
veloc
analysi
sva
confirm
trimer
format
sediment
coeffici
correspond
kda
kda
respect
agre
theoret
molecular
mass
trimer
kda
trimer
kda
strikingli
optim
four
residu
mostli
display
trimer
form
shown
singl
peak
use
sva
obtain
molecular
mass
kda
tabl
fig
next
examin
natur
stabil
secondari
structur
trimer
nhr
oligom
use
cd
spectroscopi
rel
helic
peptid
typic
extrapol
mean
residu
ellipt
nm
peptid
form
partial
helic
structur
helic
notabl
cd
spectra
trimer
assembl
consist
dramat
improv
content
rang
thermal
unfold
transit
tm
determin
respect
suggest
stabil
individu
helic
contribut
significantli
helic
trimer
stabil
tabl
addit
tm
valu
depend
peptid
concentr
demonstr
selfassoci
speci
fig
togeth
cd
sva
data
consist
fold
form
thermal
stabl
trimer
coiledcoil
design
subsequ
isopeptid
bridgeteth
trimer
coil
coil
construct
via
interhel
acyl
transfer
reaction
fig
reversephas
rp
hplc
show
nearli
complet
reaction
sbn
appear
new
peak
h
base
malditofm
analysi
peak
assign
transfer
product
interchain
acyl
transfer
reaction
confirm
tricinesodium
dodecyl
gel
electrophoresi
sampl
taken
reaction
mixtur
differ
time
store
page
analysi
consist
rphplc
analysi
also
wit
disappear
sbn
appear
new
band
lower
mobil
h
reaction
time
evidenc
rphplc
sdspage
neither
sbn
sbn
disappear
incub
h
consist
previou
data
indic
posit
correl
oligom
stabil
acyl
transfer
rate
test
specif
acyl
transfer
reaction
sbn
sbn
control
peptid
gener
reactiv
ly
upstream
ly
residu
mutat
arg
tabl
reaction
observ
absenc
activ
site
acyl
acceptor
indic
benzyl
thioestermodifi
glu
e
posit
specif
interact
residu
ly
adjac
nhelix
g
posit
rather
residu
ly
f
posit
fig
next
trimer
state
verifi
use
sva
tabl
cd
spectra
show
form
typic
structur
content
respect
dramat
higher
strikingli
coval
stabil
trimer
npeptid
exhibit
much
higher
melt
temperatur
tm
unbridg
tabl
test
effect
isopeptid
bridgeteth
thermal
stabil
helic
trimer
incub
mixtur
crosslink
ntrimer
uncrosslink
counterpart
wide
rang
temperatur
order
elimin
interfer
origin
differ
proteas
contamin
prepar
much
greater
loss
uncrosslink
ntrimer
note
contrari
isopeptid
bondteth
trimer
lost
solut
temperatur
test
fig
measur
inhibitori
activ
trimer
nhelic
appli
envmedi
fusion
assay
assay
display
moder
inhibitori
activ
effect
concentr
valu
nm
tabl
comparison
show
significantli
improv
inhibitori
activ
despit
fold
trimer
coil
coil
strikingli
stabil
ntrimer
intermolecular
isopeptid
bond
dramat
increas
inhibitori
activ
sequenc
remark
similar
natur
occur
nhr
sequenc
effect
inhibitor
envmedi
fusion
valu
nm
similar
clinic
use
fusion
inhibitor
potent
repres
chimer
npeptid
fusion
inhibitor
high
also
exhibit
promis
inhibitori
potenc
next
test
inhibitori
activ
isopeptid
bondteth
ntrimer
replic
laboratoryadapt
primari
strain
good
correl
inhibit
envmedi
fusion
inhibit
infect
observ
tabl
furthermor
ntrimer
display
low
cytotox
toward
cell
tabl
observ
subnanomolar
activ
stabil
ntrimer
suggest
excel
mimic
nhr
region
prehairpin
intermedi
suitabl
futur
studi
drug
candid
use
peptid
treatment
hivaid
patient
limit
increas
resist
high
sensit
proteolyt
enzym
present
work
isopeptid
bondstabil
ntrimer
potent
inhibit
seri
strain
valu
rang
nm
nm
tabl
other
previous
shown
variant
contain
mutat
giv
motif
amino
acid
givqqqnnll
locat
nhr
region
main
target
site
ntrimerbas
fusion
inhibitor
inhibit
entri
target
chr
region
mutat
viral
nhr
region
expect
affect
bind
ntrimerbas
fusion
inhibitor
viral
chr
region
therefor
wellfold
ntrimerbas
fusion
inhibitor
advantag
cpeptid
fusion
inhibitor
target
giv
motifcontain
nhr
region
thu
avoid
crossdrug
resist
chrbase
agent
addit
exhibit
dramat
increas
vitro
metabol
stabil
proteinas
k
broadspectrum
serin
proteinas
solut
liver
kidney
homogen
well
rat
plasma
suggest
good
potenti
drug
candid
develop
fig
drug
discoveri
perspect
compound
possess
high
potenc
action
rel
offtarget
side
effect
optim
adm
absorpt
distribut
metabol
excret
properti
nomin
ideal
candid
given
tight
specif
targetbind
peptid
repres
excel
start
point
design
potenti
therapeut
har
bioactiv
peptid
eg
target
coil
coil
domain
assembl
viral
fusion
develop
highli
select
potent
antivir
agent
minim
system
toxic
success
clinic
applic
unfortun
releg
salvag
treatment
option
mostli
due
acceler
emerg
variant
rapid
proteolysi
high
cost
manufactur
proteolyt
shortcom
render
dosag
mg
subcutan
twice
daili
result
increas
cost
treatment
poor
patient
complianc
present
work
isopeptid
bridgeteth
nhr
trimer
coiledcoil
total
differ
speci
compar
structur
bind
target
thu
effect
overcom
hiv
drug
resist
although
cost
produc
isopeptid
bondteth
ntrimer
would
slightli
higher
much
higher
resist
proteolyt
degrad
help
prolong
exist
drug
molecul
circulatori
system
would
dramat
decreas
cost
treatment
improv
treatment
complianc
patient
qualiti
life
worth
note
inhibit
interact
wide
regard
challeng
task
due
extens
flat
larg
interfaci
area
well
noncontigu
bind
compar
chimer
npeptid
recapitul
nhr
helic
trimer
absenc
auxiliari
protein
domain
enabl
interact
target
gener
effect
antivir
activ
addit
isopeptid
bondteth
ntrimer
mimet
may
outperform
disulfidebond
chimer
npeptid
term
proteolyt
stabil
disulfid
possibl
cleav
via
extracellular
thiolcontain
molecul
taken
togeth
construct
nhrtrimer
mimet
good
potenti
develop
effect
safe
longlast
fusion
inhibitor
test
abil
stabil
nhrtrimer
mimet
effect
bind
nativ
chr
ligand
nativ
n
page
sizeexclus
hplc
sehplc
cd
sva
perform
npage
coval
stabil
npeptid
appear
result
net
posit
charg
similar
observ
stabil
ntrimer
form
stabl
complex
target
peptid
evidenc
new
band
migrat
lower
rate
compar
cpeptid
concomit
near
disappear
band
fig
specif
interact
ntrimer
chr
confirm
use
sehplc
fig
addit
interact
also
studi
use
cd
compar
spectrum
mixtur
specnc
mathemat
sum
isol
peptid
specn
specc
differ
signal
indic
interact
shown
fig
coval
stabil
ntrimer
interact
form
complex
increas
comparison
correspond
specn
specc
valu
confirm
npage
sehplc
result
final
heterogen
state
stabil
ntrimer
peptid
ascertain
sva
fig
combin
data
indic
engin
nhrtrimer
mimet
abl
associ
chr
region
form
heterogen
inhibit
entri
target
cell
conclus
report
effect
strategi
construct
mimet
nhr
trimer
coiledcoil
contain
exogen
trimer
scaffold
studi
reveal
nhr
trimer
coil
coil
homolog
natur
occur
protein
sequenc
extraordinari
thermost
contribut
posit
promis
inhibit
fusion
broad
spectrum
laboratoryadapt
primari
isol
includ
resist
clinic
use
addit
tertiari
structur
integr
make
less
sensit
proteolysi
compar
unstructur
peptid
given
common
featur
underli
class
fusion
protein
coiledcoil
recapitul
methodolog
show
high
potenti
produc
nhrtrimer
mimet
class
envelop
virus
moreov
approach
could
extend
isol
certain
trimer
basic
scientif
therapeut
applic
base
ubiquit
helic
interact
found
natur
